Australian adults with bronchiectasis

The first report from the Australian Bronchiectasis Registry

Simone K. Visser, Peter T.P. Bye, Greg J. Fox, Lucy D. Burr, Anne B. Chang, Chien Li Holmes-Liew, Paul King, Peter G. Middleton, Graeme P. Maguire, Daniel Smith, Rachel M. Thomson, Enna Stroil-Salama, Warwick J. Britton, Lucy C. Morgan

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background/Objective: There are no large, multi-centre studies of Australians with bronchiectasis. The Australian Bronchiectasis Registry (ABR) was established in 2015 to create a longitudinal research platform. We aimed to describe the baseline characteristics of adult ABR participants and assess the impact of disease severity and exacerbation phenotype on quality of life (QoL).

Methods: The ABR is a centralised database of patients with radiologically confirmed bronchiectasis unrelated to cystic fibrosis. We analysed the baseline data of adult patients (≥18 years).

Results: From March 2016–August 2018, 799 adults were enrolled from 14 Australian sites. Baseline data were available for 589 adults predominantly from six tertiary centres (420 female, median age 71 years (interquartile range 64–77), 14% with chronic Pseudomonas aeruginosa infection). Most patients had moderate or severe disease based on the Bronchiectasis Severity Index (BSI) (84%) and FACED (59%) composite scores. Using Global Lung function Initiative-2012 reference equations, the majority of patients (48%) had normal spirometry; only 34% had airflow obstruction (FEV1/FVC < LLN). Disease severity scores (BSI and FACED) were negatively correlated with QoL-Bronchiectasis domain scores (rs between −0.09 and −0.58). The frequent exacerbator phenotype (≥3 in the preceding year) was identified in 23%; this group had lower scores in all QoL-B domains (p ≤ 0.001) and more hospitalisations (p < 0.001) than those with <3 exacerbations.

Conclusions: The largest cohort of Australian adults with bronchiectasis has been described. Using contemporary criteria, most patients with bronchiectasis did not have airflow obstruction. The frequent exacerbation trait connotes poorer QoL and greater health-care utilisation.
Original languageEnglish
Pages (from-to)97-103
Number of pages7
JournalRespiratory Medicine
Volume155
DOIs
Publication statusPublished - Aug 2019

Fingerprint

Bronchiectasis
Registries
Quality of Life
Patient Acceptance of Health Care
Phenotype
Pseudomonas Infections
Spirometry
Cystic Fibrosis
Pseudomonas aeruginosa
Disease Progression
Hospitalization
Databases
Lung

Cite this

Visser, S. K., Bye, P. T. P., Fox, G. J., Burr, L. D., Chang, A. B., Holmes-Liew, C. L., ... Morgan, L. C. (2019). Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry. Respiratory Medicine, 155, 97-103. https://doi.org/10.1016/j.rmed.2019.07.016
Visser, Simone K. ; Bye, Peter T.P. ; Fox, Greg J. ; Burr, Lucy D. ; Chang, Anne B. ; Holmes-Liew, Chien Li ; King, Paul ; Middleton, Peter G. ; Maguire, Graeme P. ; Smith, Daniel ; Thomson, Rachel M. ; Stroil-Salama, Enna ; Britton, Warwick J. ; Morgan, Lucy C. / Australian adults with bronchiectasis : The first report from the Australian Bronchiectasis Registry. In: Respiratory Medicine. 2019 ; Vol. 155. pp. 97-103.
@article{a5a02ba6eb1547ba80204ac524d71500,
title = "Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry",
abstract = "Background/Objective: There are no large, multi-centre studies of Australians with bronchiectasis. The Australian Bronchiectasis Registry (ABR) was established in 2015 to create a longitudinal research platform. We aimed to describe the baseline characteristics of adult ABR participants and assess the impact of disease severity and exacerbation phenotype on quality of life (QoL).Methods: The ABR is a centralised database of patients with radiologically confirmed bronchiectasis unrelated to cystic fibrosis. We analysed the baseline data of adult patients (≥18 years).Results: From March 2016–August 2018, 799 adults were enrolled from 14 Australian sites. Baseline data were available for 589 adults predominantly from six tertiary centres (420 female, median age 71 years (interquartile range 64–77), 14{\%} with chronic Pseudomonas aeruginosa infection). Most patients had moderate or severe disease based on the Bronchiectasis Severity Index (BSI) (84{\%}) and FACED (59{\%}) composite scores. Using Global Lung function Initiative-2012 reference equations, the majority of patients (48{\%}) had normal spirometry; only 34{\%} had airflow obstruction (FEV1/FVC < LLN). Disease severity scores (BSI and FACED) were negatively correlated with QoL-Bronchiectasis domain scores (rs between −0.09 and −0.58). The frequent exacerbator phenotype (≥3 in the preceding year) was identified in 23{\%}; this group had lower scores in all QoL-B domains (p ≤ 0.001) and more hospitalisations (p < 0.001) than those with <3 exacerbations.Conclusions: The largest cohort of Australian adults with bronchiectasis has been described. Using contemporary criteria, most patients with bronchiectasis did not have airflow obstruction. The frequent exacerbation trait connotes poorer QoL and greater health-care utilisation.",
keywords = "Bronchiectasis, Exacerbations, Phenotype, Quality of life, Registry, Respiratory function tests",
author = "Visser, {Simone K.} and Bye, {Peter T.P.} and Fox, {Greg J.} and Burr, {Lucy D.} and Chang, {Anne B.} and Holmes-Liew, {Chien Li} and Paul King and Middleton, {Peter G.} and Maguire, {Graeme P.} and Daniel Smith and Thomson, {Rachel M.} and Enna Stroil-Salama and Britton, {Warwick J.} and Morgan, {Lucy C.}",
year = "2019",
month = "8",
doi = "10.1016/j.rmed.2019.07.016",
language = "English",
volume = "155",
pages = "97--103",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "Global Science Books",

}

Visser, SK, Bye, PTP, Fox, GJ, Burr, LD, Chang, AB, Holmes-Liew, CL, King, P, Middleton, PG, Maguire, GP, Smith, D, Thomson, RM, Stroil-Salama, E, Britton, WJ & Morgan, LC 2019, 'Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry', Respiratory Medicine, vol. 155, pp. 97-103. https://doi.org/10.1016/j.rmed.2019.07.016

Australian adults with bronchiectasis : The first report from the Australian Bronchiectasis Registry. / Visser, Simone K.; Bye, Peter T.P.; Fox, Greg J.; Burr, Lucy D.; Chang, Anne B.; Holmes-Liew, Chien Li; King, Paul; Middleton, Peter G.; Maguire, Graeme P.; Smith, Daniel; Thomson, Rachel M.; Stroil-Salama, Enna; Britton, Warwick J.; Morgan, Lucy C.

In: Respiratory Medicine, Vol. 155, 08.2019, p. 97-103.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Australian adults with bronchiectasis

T2 - The first report from the Australian Bronchiectasis Registry

AU - Visser, Simone K.

AU - Bye, Peter T.P.

AU - Fox, Greg J.

AU - Burr, Lucy D.

AU - Chang, Anne B.

AU - Holmes-Liew, Chien Li

AU - King, Paul

AU - Middleton, Peter G.

AU - Maguire, Graeme P.

AU - Smith, Daniel

AU - Thomson, Rachel M.

AU - Stroil-Salama, Enna

AU - Britton, Warwick J.

AU - Morgan, Lucy C.

PY - 2019/8

Y1 - 2019/8

N2 - Background/Objective: There are no large, multi-centre studies of Australians with bronchiectasis. The Australian Bronchiectasis Registry (ABR) was established in 2015 to create a longitudinal research platform. We aimed to describe the baseline characteristics of adult ABR participants and assess the impact of disease severity and exacerbation phenotype on quality of life (QoL).Methods: The ABR is a centralised database of patients with radiologically confirmed bronchiectasis unrelated to cystic fibrosis. We analysed the baseline data of adult patients (≥18 years).Results: From March 2016–August 2018, 799 adults were enrolled from 14 Australian sites. Baseline data were available for 589 adults predominantly from six tertiary centres (420 female, median age 71 years (interquartile range 64–77), 14% with chronic Pseudomonas aeruginosa infection). Most patients had moderate or severe disease based on the Bronchiectasis Severity Index (BSI) (84%) and FACED (59%) composite scores. Using Global Lung function Initiative-2012 reference equations, the majority of patients (48%) had normal spirometry; only 34% had airflow obstruction (FEV1/FVC < LLN). Disease severity scores (BSI and FACED) were negatively correlated with QoL-Bronchiectasis domain scores (rs between −0.09 and −0.58). The frequent exacerbator phenotype (≥3 in the preceding year) was identified in 23%; this group had lower scores in all QoL-B domains (p ≤ 0.001) and more hospitalisations (p < 0.001) than those with <3 exacerbations.Conclusions: The largest cohort of Australian adults with bronchiectasis has been described. Using contemporary criteria, most patients with bronchiectasis did not have airflow obstruction. The frequent exacerbation trait connotes poorer QoL and greater health-care utilisation.

AB - Background/Objective: There are no large, multi-centre studies of Australians with bronchiectasis. The Australian Bronchiectasis Registry (ABR) was established in 2015 to create a longitudinal research platform. We aimed to describe the baseline characteristics of adult ABR participants and assess the impact of disease severity and exacerbation phenotype on quality of life (QoL).Methods: The ABR is a centralised database of patients with radiologically confirmed bronchiectasis unrelated to cystic fibrosis. We analysed the baseline data of adult patients (≥18 years).Results: From March 2016–August 2018, 799 adults were enrolled from 14 Australian sites. Baseline data were available for 589 adults predominantly from six tertiary centres (420 female, median age 71 years (interquartile range 64–77), 14% with chronic Pseudomonas aeruginosa infection). Most patients had moderate or severe disease based on the Bronchiectasis Severity Index (BSI) (84%) and FACED (59%) composite scores. Using Global Lung function Initiative-2012 reference equations, the majority of patients (48%) had normal spirometry; only 34% had airflow obstruction (FEV1/FVC < LLN). Disease severity scores (BSI and FACED) were negatively correlated with QoL-Bronchiectasis domain scores (rs between −0.09 and −0.58). The frequent exacerbator phenotype (≥3 in the preceding year) was identified in 23%; this group had lower scores in all QoL-B domains (p ≤ 0.001) and more hospitalisations (p < 0.001) than those with <3 exacerbations.Conclusions: The largest cohort of Australian adults with bronchiectasis has been described. Using contemporary criteria, most patients with bronchiectasis did not have airflow obstruction. The frequent exacerbation trait connotes poorer QoL and greater health-care utilisation.

KW - Bronchiectasis

KW - Exacerbations

KW - Phenotype

KW - Quality of life

KW - Registry

KW - Respiratory function tests

UR - http://www.scopus.com/inward/record.url?scp=85069541227&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2019.07.016

DO - 10.1016/j.rmed.2019.07.016

M3 - Article

VL - 155

SP - 97

EP - 103

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

ER -